Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkArthur J. Atkinson(National Institutes of Health)Clinical Pharmacology & TherapeuticsMarch 1, 200110.1067/mcp.2001.113989Cited by 6,609SaveCiteExport RISWatch citationsAbstractRelated PapersDistinct types of diffuse large B-cell lymphoma identified by gene expression profilingAsh A. Alizadeh, Michael B. Eisen, R. Eric Davis et al.|Nature|2000|9.9kSurrogate endpoints in clinical trials: Definition and operational criteriaRoss L. Prentice|Statistics in Medicine|1989|2kSurrogate End Points in Clinical Trials: Are We Being Misled?Thomas R. Fleming, David L. DeMets|Annals of Internal Medicine|1996|1.6kLong-Term Effects of Pravastatin on Plasma Concentration of C-reactive ProteinPaul M. Ridker, Nader Rifai, Marc A. Pfeffer et al.|Circulation|1999|1.5kStatistical validation of intermediate endpoints for chronic diseasesLaurence S. Freedman, Barry I. Graubard, Arthur Schatzkin|Statistics in Medicine|1992|654